Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class ActionNovember 19, 2025 9:12 AM EST | Source: Levi & Korsinsky, LLPNew York, New York--(Newsfile Corp. - November 19, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submissio ...

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that during the class period, the defendants made false and misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, which led to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions of dollars for investors [4].

MLTX CLASS NOTICE: BFA Law Alerts MoonLake Immunotherapeutics Investors of the Pending Securities Fraud Class Action and Upcoming December 15 DeadlineNovember 18, 2025 3:33 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 18, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the fe ...

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc, alleging that the company misled investors regarding the performance of its North America Fiber Cement segment during the specified Class Period from May 20, 2025, to August 18, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by the national plaintiffs' law firm Berger Montague on behalf of investors who purchased James Hardie common stock or American Depositary Shares during the Class Period [1][2]. - Investors have until December 23, 2025, to seek appointment as lead plaintiff representatives of the class [2]. Group 2: Allegations Against the Company - The complaint alleges that James Hardie misrepresented the strength of its core North America Fiber Cement segment, claiming that demand was strong and inventory levels were normal, despite knowledge of distributors destocking inventory by April and early May 2025 [3]. - On August 19, 2025, the company disclosed a 12% decline in the segment, attributing it to "normalization of channel inventories" and warned of continued weakness, leading to a stock price drop of over 34% [4].

New York, New York--(Newsfile Corp. - November 18, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=177904&wire=5&utm_campaign=29or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.Can ...

SAN DIEGO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Peters v. MoonLake Immunotherapeutics, No. 25-cv-08612 (S.D.N.Y.) – seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock and charges MoonLake as well as certain of MoonLake’s executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Moon ...

Core Insights - The article discusses the potential mispricing of sonelokimab's approval probability and commercial potential in the biotech sector, suggesting that the market has not accurately assessed its value [4]. Group 1: Author's Background - The author has over a decade of experience in financial research, investment advisory, and banking analytics, with a focus on evaluating institutional strengths and weaknesses [2]. - The author's academic background includes a Bachelor's in Business Economics and an MBA, which informs their analytical approach to market valuation [2]. - Since retiring from full-time industry work in 2018, the author has concentrated on independent investment research, particularly in overlooked and under-owned assets [2]. Group 2: Research Focus - The research emphasizes the importance of macroeconomic trends, data science, and qualitative analysis to uncover actionable insights and market inefficiencies [2]. - The author aims to provide value to investors by bridging analytical rigor with strategic foresight, focusing on market psychology and valuation [2]. Group 3: Investment Position - The author holds a beneficial long position in MLTX shares, indicating a personal financial interest in the stock [3].

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The deadline to move the court to serve as lead plaintiff is December 15, 2025, with the lead plaintiff acting on behalf of other class members [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Allegations - The complaint alleges that during the class period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5].

MLTX SECURITIES ALERT: BFA Law Notifies MoonLake Immunotherapeutics Investors of Important December 15 Securities Class Action DeadlineNovember 17, 2025 3:18 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securitie ...

Core Viewpoint - A securities class action has been filed against MoonLake Immunotherapeutics following the announcement of poor Phase 3 trial results for its product candidate sonelokimab (SLK), leading to a significant drop in share price [1][2]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on treating skin inflammatory diseases, specifically targeting cytokines IL-17A and IL-17F [3][4]. Trial Results and Market Reaction - The Phase 3 trial results revealed that only one of the two trials achieved statistical significance, with efficacy substantially lower than that of a competitor's product, BIMZELX [6]. - Following the announcement, MoonLake's share price plummeted by $55.75, approximately 90%, on September 29, 2025 [2][6]. Allegations of Misleading Information - The lawsuit claims that MoonLake misled investors regarding SLK's trial design and efficacy, asserting that the company made false statements about the advantages of SLK over BIMZELX [5][6]. - Specific allegations include misleading claims about the clinical benefits of SLK's Nanobody structure compared to traditional monoclonal antibodies [5]. Legal Proceedings - The class action lawsuit is focused on the accuracy of MoonLake's statements about SLK's trial design and data, with a class period defined from March 10, 2024, to September 29, 2025 [3][4]. - The lead plaintiff deadline for the lawsuit is set for December 15, 2025 [3].